新規頻尿・尿失禁治療剤 (±)-4-diethylamino-1,1-dimethylbut-2-yn-1-yl 2-cyclohexyl-2-hydtoxy-2-phenylacetate monohydrochloride monohydrate (NS-21) の抗原性試験

DOI Web Site Web Site 参考文献5件

書誌事項

タイトル別名
  • ANTIGENICITY STUDY OF (±)-4-DIETHYLAMINO-1, 1-DIMETHYLBUT-2-YN-1-YL 2-CYCLOHEXYL-2-HYDROXY-2-PHENYLACETATE MONOHYDROCHLORIDE MONOHYDRATE (NS-21), A NOVEL DRUG FOR URINARY FREQUENCY AND INCONTINENCE
  • 新規頻尿・尿失禁治療剤(+)-4-diethylamino-1,1-dimethylbut-2yn-1-yl2-cyclohexyl-2-hydroxy-2-phenylacetate monohydrochloride monohydrate(NS-21)の抗原性試験
  • シンキ ヒンニョウ ニョウ シッキン チリョウザイ+4 diethylamin

この論文をさがす

抄録

An antigenicity study of (±)-4-diethyldmino-1, 1-dimethylbut-2-yn-1-yl 2-cyclohexyl-2-hydroxy-2-phenylacetate monohydrochloride monohydrate (NS-21), a new drug for the treatment of urinary frequency and incontinence, was conducted in Hartley guinea pigs and BALB/cAnN mice. The following results were obtained. No active systemic anaphylaxis reactions were found in guinea pigs immunized by subcutaneous injection of NS-21 alone or in combination with Freund's complete adjuvant (FCA). No 24-hr heterologous passive cutaneous anaphylaxis reactions were elicited in rats by sera from mice immunized by intraperitoneal injection of NS-21 alone or in combination with 3% aluminum hydroxide gel. No passive hemagglutination reactions were elicited by sera from mice immunized by subcutaneous injection of NS-21 in combination with FCA. These results show that NS-21 has no antigenicity under the present experimental conditions.

収録刊行物

参考文献 (5)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ